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Abstract — Expression, purification and structure determination of recombinant proteins is a fundamental 
requirement for a variety of biological applications, from exploratory research to pharmaceutical drug discovery.
Exploiting the expertise and the strategic location of the laboratories of Elettra Synchrotron of Trieste, we 
have invested to create a dedicated center for protein production and characterization in the newly renovated 
structural biology lab of Elettra. The PROTEO project aims to offer a specialized support to research groups that 
need to obtain pure recombinant  proteins for functional or structural studies. The core protein production unit 
is equipped to express/purify proteins with high efficiency in prokaryotic and eukaryotic systems and is setting 
up HT protocols. Currently, ten different projects are running in the lab. For each project, constructs design 
followed by fast multi-cloning approach has been performed leading to the combined evaluation of a number 
of different expression data: most adequate expression systems were chosen and the purification protocols 
were optimized to obtain correctly folded, functional and stable proteins for structural studies.
In this paper we present the organization of the PROTEO protein production platform and a number of studies 
ongoing.
Index Terms — protocols were optimized to obtain correctly folded, functional and stable proteins for 
structural studies
_____________________________________________________________________ 
1 BACKGROUND
Expression and purification of recombinant proteins is a fundamental requirement for a variety of 
biological research applications, from exploratory research to pharmaceutical drug discovery. The past 
10 years have witnessed a fast evolution of postgenomic technologies. One of the fields that was 
highly boosted by the ‘’omics’’ initiatives is the production of recombinant proteins, which experienced 
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an extraordinary increase of throughput and results, fueling thus the comprehension of challenging 
scientific questions (1). 
2 OBJECTIVES
Organize and validate a protein production lab by semi-automated approaches of cloning and 
expression of multiple protein targets in E.coli, insect cell and mammalian expression systems. Give 
specialized support to collaborators to get their protein of interest for functional and structural studies. 
Focus on proteins that are relevant for cancer diagnostic and therapy. 
3 APPROACH & METHODS
3.1  General approach
The protein production workflow is schematized in Fig.1. Critical steps are the construct design and the 
parallel evaluation of multiple samples/variables. The “Multiple Cloning” and the “Multiple-Parameter 
Test-Expression” can be automated by set up of robotized protocols (Liquid Handling Freedom EVO 
150 – TECAN).
3.2  Methods
Constructs design is based on bioinformatic analysis and experimental data. The defined sequences 
are PCR amplified  and subcloned by Gateway® (Invitrogen) or LIC cloning methods that are suitable 
for parallel/robotic processes (2, 3). 
Expression constructs are fused with different N-terminal tags accordingly with the project needs, and 
all contain an His6-tag to allow parallel affinity purification on methal chelated resin. Tags are cleaved 
by specific protease (TEV  or Prescission protease). Purification optimization and scale up is done 
exploiting all chromatographic techniques available in the lab. Usually, the affinity chromatography 
step is followed by IEX and SEC. Quality control is done by SDS-PAGE and Western blot. When required, 
activity assay is performed. Thermal stability assay is done by RT-PCR using CFX96-BioRad (4).   
4 RESULTS
Our production pipeline is currently composed of about 10 proteins, derived from active collaborations 
with PROTEO’s partners and other external groups. These proteins are targets of pharmacological 
interest for cancer therapy. 
Accordingly to the protein intrinsic features and the scope of the work, we can choose to  express 
the protein in E.coli, insect or mammalian cells. Parallel evaluation of multivariate parameters (strains, 
induction mode, T°, t) leads to identification of optimal expression conditions. Below are shown some 
examples of results obtained for different proteins along the expression-purification workflow:
Evaluation of the expression levels of USP1 obtained by comparing different E.coli strains with various 
expression vectors (table 1)
• SDS-PAGE analysis from affinity-purification steps of three proteins (Fig. 2: a. Pin1; b. USP18; c. Her2)
• Thermofluor assay to evaluate the stability of purified proteins. In Fig. 3 is reported the thermal-shift 
plot of purified Pin1 WT, that results to have a Tm=53.8 °C ± 1.2°. Interestingly after preserving the 
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Fig. 2: SDS-PAGE analysis from affinity-purification steps of three proteins (a. Pin1; b. USP18; c. Her2). Pin1 expressed 
in E.coli (BL21); b. hUSP18 in insect cells (Sf9); c.  Her2-Fc in mammalian cells (HEK293)
Fig. 3:Thermofluor assay to evaluate 
the stability of purified proteins. In 
the panel is reported the thermal-
shift plot of purified Pin1 WT, that 
results to have a Tm=53.8 °C ± 1.2°. 
Tab1: Table of the total levels  of expression otained for human USP1full-length expressed in different E.coli strain. RP 
strains express higher amount of proteins, although insoluble.
protein for more than 3 weeks at 4°C, the Tm and the profile is almost unchanged, suggesting that the 
protein is stable in the storage buffer.  
• Improve yields by growth in bioreactor: Pilot study to set  up expression condition in a 2L bioreactor 
(Biostat B, Sartorius) has improved the yield of final purified Pin1, going form 20 mg/L to 80 mg/L (Fig. 4). 
292
5 POTENTIAL NEW PRODUCTS & SERVICES
The aim is to offer a specialized support to research laboratories (public or private) for a rapid 
identification of best conditions for recombinant protein production. Moreover, the close contact 
with synchrotron beam lines such as SAXS and X-ray diffraction, will facilitate access of biomedical 
researcher to structural biology approaches.  On the long term our objective will be to create a tailored 
service that will enhance efficiency of basic and applied research in the local area.
6 CURRENT COLLABORATIONS
• Francesca Demarchi – LNCIB, Trieste (PP2, Proteo); 
• Gianni Del Sal Lab – LNCIB, Trieste, (PP2, Proteo); 
• Claudio Brancolini – University of Udine (PP5, Proteo);   
• Ario de Marco – University of Nova Gorica (PP1, Proteo); 
• Jan Mavri – COBIK, Ajdovščina (PP4, Proteo); 
• Sabrina Pricl – University of Trieste; 
• Gianmaria Severini – IRCCS Burlo Garofolo – Trieste; 
7  CONTACT OR COLLABORATIONS NEEDED
The PROTEO protein production facility would like to collaborate with:
Protein chemistry experts for N-terminal sequencing and mass spectrometry ( ESI-MS, MALDI);
Pharmacologist and medicinal chemists, to develop small molecules that will interact/inhibit the 
protein targets we are interested in;
Anyone who needs to over-express and purify its protein and do not have the suitable resources. 
Fig. 4: bioreactor Biostat B, (Sartorius) assembled with a 2L vessel, and parameters used to express Pin1. 
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8 FUNDS NEEDED
8.1  For basic research (investigation of biological mechanisms): 50.000 € 
8.2  For applied research (solutions for real-world problems): 100.000 €
8.3  For pilot & demonstrator activities (to develop a prototype): 150.000 €
9  CONCLUSIONS
Thanks to the PROTEO project we could start to implement a new protein production facility at Elettra’s 
Structural Biology Laboratory. Collaborating with external research laboratories we could set up the 
expression of different recombinant proteins in E.coli, insect and mammalian cells and validate several 
expression vectors and purification protocols. Some proteins have been obtained in quantity and 
quality suitable for further experiments (i.e. assay set up, crystallization trials, protein-protein interaction 
studies). Such a service will allow an increase in efficiency and scientific productivity, saving thus time 
and money.  
REFERENCES
1) Protein Production and Purification, SGC et al, Nat Methods. 2008 Feb;5(2):135-46. doi: 10.1038/
nmeth.f.202.
2) Savitsky P. , et al. J Struct Biol. 2010 Oct; 172(1): 3-13, doi:10.1016/j.jsb.2010.06.008.
3) Luna-Vargas MP et al. J Struct Biol. 2011 Aug;175(2):113-9. doi: 10.1016/j.jsb.2011.03.017..
4) Ericsson UB et al, Anal.Biochem. 2006; 357:289-298. doi: 10.1016/j.ab.2006.07.27
ACKNOWLEDGMENT
The PROTEO Project is funded under the Cross-Border Cooperation Program Italy - Slovenia 2007-2013 
by the European Regional Development Fund and national funds.
